News

Drug Patent & Exclusivity Expiration Report - Week of Oct 21 2024

Views: 63     Author: Unibest Industrial     Publish Time: 2024-10-22      Origin: Site

facebook sharing button
twitter sharing button
line sharing button
wechat sharing button
linkedin sharing button
pinterest sharing button
sharethis sharing button

Patent and Exclusivity Expirations Report

Report generated for the week of 2024-10-21 by Unibest Digital Center. Current analysis scope only include the US FDA.

Summary of Expirations

This week, there are 3 drugs in the patent and exclusivity list. They are:
- BRISTOL-MYERS SQUIBB CO's ABRAXANE, containing active ingredient PACLITAXEL
- VERTEX PHARMACEUTICALS INC's TRIKAFTA (COPACKAGED), containing active ingredient ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR
- BAUSCH AND LOMB INC's XIPERE, containing active ingredient TRIAMCINOLONE ACETONIDE


Patents Expiring This Week

PACLITAXEL - POWDER;INTRAVENOUS - ABRAXANE

From BRISTOL-MYERS SQUIBB CO

100MG/VIAL

Approved in Jan 7, 2005, used as Reference Listed Drug and Reference Standard

There are 15 future patent(s) for this application. The earliest expires on 2025-04-27, and the latest expires on 2034-07-12.

Patent NoPatent Use CodePatent Use DefinitionPatent Expiration Date
7820788U-1290TREATMENT OF LUNG CANCER2024-10-27
7820788U-1092TREATMENT OF BREAST CANCER2024-10-27
7820788U-1434TREATMENT OF PANCREATIC CANCER2024-10-27


Exclusivities Expiring This Week

ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - GRANULES;ORAL - TRIKAFTA (COPACKAGED)

From VERTEX PHARMACEUTICALS INC

100MG, 75MG, 50MG;75MG

Approved in Apr 26, 2023, used as Reference Listed Drug and Reference Standard

There are 2 future exclusivity(ies) for this drug product. The earliest expires on 2026-04-26, and the latest expires on 2030-04-26.

Exclusivity DateExclusivity Use Definition
2024-10-21NEW CHEMICAL ENTITY

80MG, 60MG, 40MG;59.5MG

Approved in Apr 26, 2023, used as Reference Listed Drug

There are 2 future exclusivity(ies) for this drug product. The earliest expires on 2026-04-26, and the latest expires on 2030-04-26.

Exclusivity DateExclusivity Use Definition
2024-10-21NEW CHEMICAL ENTITY

ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TABLET;ORAL - TRIKAFTA (COPACKAGED)

From VERTEX PHARMACEUTICALS INC

100MG,75MG,50MG; 150MG

Approved in Oct 21, 2019, used as Reference Listed Drug and Reference Standard

There are 3 future exclusivity(ies) for this drug product. The earliest expires on 2026-10-21, and the latest expires on 2028-06-08.

Exclusivity DateExclusivity Use Definition
2024-10-21NEW CHEMICAL ENTITY

50MG,37.5MG,25MG; 75MG

Approved in Jun 8, 2021, used as Reference Listed Drug

There are 3 future exclusivity(ies) for this drug product. The earliest expires on 2026-10-21, and the latest expires on 2028-06-08.

Exclusivity DateExclusivity Use Definition
2024-10-21NEW CHEMICAL ENTITY

TRIAMCINOLONE ACETONIDE - SUSPENSION;INJECTION - XIPERE

From BAUSCH AND LOMB INC

40MG/ML

Approved in Oct 22, 2021, used as Reference Listed Drug and Reference Standard

There are no future exclusivities for this application.

Exclusivity DateExclusivity Use Definition
2024-10-22NEW PRODUCT